Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
NRG Oncology
National Cancer Institute (NCI)
State University of New York - Upstate Medical University
National Cancer Institute (NCI)
University of Texas Southwestern Medical Center
NYU Langone Health
Swiss Cancer Institute
Barts & The London NHS Trust
Taizhou Hospital
AHS Cancer Control Alberta
AHS Cancer Control Alberta
University of Michigan Rogel Cancer Center
Jiangsu Cancer Institute & Hospital
AHS Cancer Control Alberta